Impact of body-mass index in the outcome of adult patients with acute myeloid leukemia
2 ABSTRACT Background.
Obesity increases the risk of treatment-related complications and reduces survival in children with acute myeloid leukemia. Little is known about the impact of obesity on the outcome of adult patients with acute myeloid leukemia.
Design and Methods.
We compared the baseline characteristics and effect on treatment and survival in 1,974 untreated adult acute myeloid leukemia patients undergoing treatment, according to international classification of body mass index.
Results.
Median BMI was 26.7 (15.5-61 ) and 63% of patients were overweight/obese. After adjustment for other confounders of age, gender, performance status, karyotype, white blood cell, platelet and peripheral blast counts, obese patients had improved complete remission rates (p-0.0046), lower rates of resistant disease (p-0.038) but similar survival and severe adverse events.
Conclusions.
In the treatment of adult AML, obesity was associated with increased response rates, no apparent increase in toxicity, and should not be an exclusion for aggressive therapy.
INTRODUCTION
Acute myeloid leukemia (AML) is a clonal hematopoietic disorder and the most common myeloid malignancy in adults. 1 Each year, ~13,000 individuals are diagnosed with AML in the United States with a median age at presentation of ~70 years. 4 Given the expected shift in age structure the projected incidence of AML is expected to increase by ~50% by 2030. 2 The prevalence of obesity has steadily increased in developed countries, 3, 4 where nearly ⅔ of adults are overweight (body-mass index [BMI] > 25). 5 Obesity is associated with an increased risk of all-cause mortality from cardiovascular causes and malignancies. 3 Associations between increased BMI and leukemia and acute promyelocytic leukemia (APL)
have been reported. 6, 7 Reduced overall survival (OS), due to higher rates of treatment-related toxicities, was noted in overweight children with AML. 8 As the effect of BMI at diagnosis in adult AML patients is unknown, we studied the prognostic impact of BMI on response, toxicity and survival in AML patients treated in SWOG studies. Induction therapies were grouped into those: (1) with "standard" doses of cytarabine (</=200 mg/m2 daily X 7 days) (n -814), (2) with higher than "standard" doses of cytarabine (at least 
DESIGN AND METHODS

Patients
Statistical analysis
CR was defined according to the Dohner criteria. 10 Induction death (ID) was defined as death within 28 days of initiating therapy. Resistant disease (RD) was defined as patients alive past 28 days of initiating therapy who never achieved CR or who relapsed within 1-year of CR.
OS was measured from the date of study entry until death from any cause, with censoring at the date of last contact. Fisher's exact test was used to test associations between categorical variables. The Kruskal-Wallis test was used to determine associations between age and BMI classes. The Wilcoxon rank-sum test was used to compare the toxicity profile according to median BMI. The Kaplan-Meier method was used to estimate median OS. 11 Cox proportional hazards models were used to assess associations with the outcome OS. 12 Logistic regression models were used to assess associations with the outcomes CR and RD. BMI was measured both as a continuous numerical variable and as a categorical variable corresponding to the WHO classes in these models (Table 2 ). For the logistic regression analyses, only the 1,080
patients with confirmed karyotype were included.
RESULTS
Baseline characteristics of the patients
The median BMI (median age 57 years, range 17-89) was 26.7 (range 15.5 to 61). Sixty four percent of patients were overweight and one quarter were obese. Table 1 lists the distribution of WHO BMI classes. No significant associations were noted between BMI class and karyotype (p = 0.88). As previously shown, increased age was associated with increased BMI 13 ; the median age was youngest in the underweight group (50 years) and oldest in the overweight group (59 years, p-value = 0.002). Also, the incidence of obesity and the median BMI tended to increased over time, whereas patients enrolled during the 1980's (S8600) had a median BMI = 24.5 (overweight/obese=45%) versus those enrolled in the early 1990's (S9031, S9126, S9333, S9500) who had a median BMI = 26.4 (overweight/obese=63%) versus those enrolled more recently (S9617, S9918, S0106) who had a median BMI = 27.7 (p<0.001) (overweight/obese = 69%, p<0.001). 
Impact of BMI on Response to Therapy and Survival
Toxicity profile according to BMI
Overweight/obese patients received higher total doses of chemotherapy. However, no significant differences in toxicities were noted in these patients (Fisher's exact test p=0.46)
nor were there differences in the median BMI in patients with or without adverse events (p=0.66).
Unadjusted and adjusted logistic regression analyses with adverse events as the outcome showed no significant association between toxicity and BMI.
DISCUSSION
The epidemic of obesity has become a global health problem. Worldwide, 2.3 billion adults will be overweight and ~1/3 of these will be considered obese by 2015. Our study is the largest dataset to determine the impact of BMI on the outcome of adult AML patients undergoing induction chemotherapy. Two-thirds of patients were overweight/obese and median BMI increased with age at diagnosis and over time. Also, in our cohort, increased BMI was associated with higher response rates and lower rates of resistance to chemotherapy, but had no impact on survival, treatment-related deaths or toxicities. These were surprising findings as obesity is associated with an increased risk of diabetes and cardiovascular disease, which can increase toxicity in such patients. 13 7
Our results contrast with those reported in children and adolescents with AML, where extreme BMIs predicted for inferior survival. Several possible explanations exist. First, the definitions of underweight and overweight were different. We used the WHO criteria 14 while
Lange et al used the Centers for Disease Control and Prevention 2000 Growth Charts. 15 Therefore, a higher proportion of adults were classified as obese (26% vs. 15%) and more children/adolescents classified as underweight (11% vs. 3%). 8 Second, obese children had increased treatment related mortality, but similar relapse risk. 8 In contrast, obese adult patients had increased response rates, with no increase in treatment-related deaths or toxicities. Reasons for these discrepancies are unclear and warrant further investigation.
The pharmacokinetic effects of obesity on daunorubucin metabolism are not well understood.
Some studies have suggested that obese patients receiving doxorubicin may have an increased drug half-life with greater drug exposure due to reduced systemic clearance.
16
Other studies, however, suggest that anthracycline dose reductions in obese patients may be associated with similar toxicities but worse outcomes. 17 It is possible that obese AML patients could have longer daunorubicin exposure, which translated into higher response rates. Two recent studies showed that daunorubicin dose intensification is associated with improved outcomes in AML, especially in younger patients. 18, 19 The lack of a clear increase in toxicity in obese patients may reflect the insensivity of current tools to measure toxicity.
Alternatively, leptins, which are increased with obesity, have been to shown to increase AML blast proliferation, which could sensitize these cells to cytotoxic agents 20 This study has clear limitations. This was a retrospective, unplanned analysis. Physicians may have been reluctant to enter obese patients with significant co-morbidities on these trials leading to patient selection bias. We have no data on confounding factors, such as 8 socioeconomic status. The tools for measuring toxicity were likely imprecise. Nonetheless, our results underscore the increasing prevalence of obesity in this population and demonstrate that obesity may be associated with increased response rates, and suggest that overweight patients should not be denied the potential benefits of aggressive therapy. 
Authorship and Disclosures
Conflict of Interest Disclosures
The authors have no conflicts of interest to report. 
